Boston Scientific Co. (NYSE:BSX) Shares Sold by Hutchens & Kramer Investment Management Group LLC

Hutchens & Kramer Investment Management Group LLC trimmed its holdings in Boston Scientific Co. (NYSE:BSX) by 7.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,290 shares of the medical equipment provider’s stock after selling 194 shares during the period. Hutchens & Kramer Investment Management Group LLC’s holdings in Boston Scientific were worth $205,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Greenup Street Wealth Management LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $1,634,000. BankPlus Wealth Management LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $262,000. Nilsine Partners LLC grew its stake in Boston Scientific by 9.0% during the 4th quarter. Nilsine Partners LLC now owns 5,285 shares of the medical equipment provider’s stock worth $472,000 after buying an additional 437 shares during the last quarter. Foundations Investment Advisors LLC bought a new position in Boston Scientific during the 4th quarter worth $296,000. Finally, Pacer Advisors Inc. grew its stake in Boston Scientific by 21.8% during the 4th quarter. Pacer Advisors Inc. now owns 138,057 shares of the medical equipment provider’s stock worth $12,331,000 after buying an additional 24,754 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BSX. Wells Fargo & Company upped their price objective on Boston Scientific from $98.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Morgan Stanley boosted their price target on Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, October 24th. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Evercore ISI boosted their price target on Boston Scientific from $82.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Mizuho upped their price objective on Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, October 24th. Three research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.26.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $102.22 on Tuesday. The business’s 50-day simple moving average is $92.26 and its 200-day simple moving average is $85.45. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. Boston Scientific Co. has a 52 week low of $60.78 and a 52 week high of $102.32. The firm has a market cap of $150.65 billion, a price-to-earnings ratio of 84.48, a P/E/G ratio of 2.63 and a beta of 0.80.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,877 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the transaction, the director now directly owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. This trade represents a 11.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Arthur C. Butcher sold 14,010 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the transaction, the executive vice president now directly owns 978 shares in the company, valued at $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,989 shares of company stock valued at $2,702,261. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.